Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | CENPE | Q02224 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 2/20 | 0.32 |
| ▸ | GIPR | P48546 | 2/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569134 | 0.89 | CENPE (0.39) | MEN1KMT2ACSNK2A1S1PR1DHODH | |
| SCHEMBL5569474 | 0.83 | P2RX3 (0.39) | MEN1KMT2ACSNK2A1S1PR1S1PR2 | |
| SCHEMBL3231108 | 0.77 | CENPE (0.41) | DHODHCENPEGCGRGIPRP2RX3 | |
| SCHEMBL5569939 | 0.76 | CSNK2A1 (0.33) | CSNK2A1TRPV3S1PR1GCGRGIPR | |
| SCHEMBL5565634 | 0.76 | GCGR (0.37) | CSNK2A1S1PR1GCGRGIPRP2RX3 | |
| SCHEMBL5565856 | 0.76 | CSNK2A1 (0.33) | CSNK2A1TRPV3S1PR1 | |
| SCHEMBL3462427 | 0.75 | CENPE (0.53) | S1PR1S1PR3DHODHCENPEP2RX3 | |
| SCHEMBL13161681 | 0.75 | CENPE (0.53) | S1PR1S1PR3DHODHCENPEP2RX3 | |
| SCHEMBL5569744 | 0.75 | THRA (0.36) | CSNK2A1S1PR1GCGRGIPRP2RX3 | |
| SCHEMBL3221912 | 0.75 | CENPE (0.56) | DHODHCENPEGCGRGIPRPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | claimed |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | MEN1 1302/4885KMT2A 1501/4885CSNK2A1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.